Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Setubal – page 4

664 clinical trials in Setubal, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Setubal at a glance
664
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

664 trials in Setubal

Open in trial search

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Neutropenia

Recruiting

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Setubal

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on cardiovascular disease prevention and treatment, including innovative approaches to reduce major cardiovascular events and stroke prevention in patients with atrial fibrillation.

  • Lipoprotein management studies
  • Stroke prevention therapies
  • Atherosclerotic disease prevention

Research aims to evaluate new therapeutic options for reducing cardiovascular risks and improving patient outcomes.

02 Neurological Disorders

Clinical investigations targeting migraine management, including specialized studies for menstrual migraine prevention and acute treatment approaches.

  • Preventive migraine treatments
  • Acute migraine interventions
  • Gender-specific migraine studies

These trials explore innovative therapeutic solutions for various types of migraines.

03 Oncology Research

Advanced studies in breast cancer and non-small cell lung cancer treatments, focusing on targeted therapies and innovative treatment combinations.

  • Hormone receptor-positive breast cancer
  • Metastatic cancer treatments
  • Immunotherapy combinations

Research focuses on developing more effective treatments for various cancer types.

04 Autoimmune Conditions

Comprehensive research into systemic lupus erythematosus and related conditions, including specialized studies for lupus nephritis.

  • Lupus treatments
  • Kidney disease management
  • Chronic urticaria studies

Trials aim to improve treatment options for patients with autoimmune disorders.

05 Metabolic Disorders

Innovative research on type 2 diabetes complications, particularly focusing on diabetic retinopathy and its progression.

  • Diabetic eye disease
  • Glycemic control studies
  • Long-term disease management

Studies evaluate new approaches to managing diabetes-related complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.